Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bph.13211 http://scihub22266oqcxt.onion/10.1111/bph.13211 C4556464!4556464!26040571     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Pharmacol 2015 ; 172 (17): 4228-37 Nephropedia Template TP {{tp|p=26040571|t=2015. Therapeutic targets of triple-negative breast cancer: a review |pdf=|usr=}}{{26040571}} gab.com Text Therapeutic targets of triple-negative breast cancer: a review JO: Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26040571 #FOAvip Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC. This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC. This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, Wnt/?-catenin and Hedgehog pathways, in addition to EGFR, PARP1, mTOR, TGF-? and angiogenesis inhibitors. Twit Text FOAVip Therapeutic targets of triple-negative breast cancer: a review ????Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=26040571 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26040571 #FOAvip English Wikipedia <ref>{{Cite pmid|26040571}}</ref> Therapeutic targets of triple-negative breast cancer: a review #MMPMID26040571 Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N Br J Pharmacol 2015[Sep]; 172 (17): 4228-37 PMID26040571show ga Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC. This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC. This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, Wnt/?-catenin and Hedgehog pathways, in addition to EGFR, PARP1, mTOR, TGF-? and angiogenesis inhibitors. äTherapeutic targets of triple-negative breast cancer: a review (epmc).pdf DeepDyve Pubget Overpricing